You are here

biosimilars

Coherus hits FDA hurdles for PD-1 drug, Neulasta biosimilar on-body injector

Coherus hits FDA hurdles for PD-1 drug, Neulasta biosimilar on-body injector

Fierce Pharma

Coherus Biosciences

Junshi Biosciences

Flag link:

Third Time Might Be a Charm for Alvotech as FDA Accepts BLA for Humira Biosimilar

Third Time Might Be a Charm for Alvotech as FDA Accepts BLA for Humira Biosimilar

BioSpace

Flag link:

Alvotech gets new FDA review for Humira biosimilar

Alvotech gets new FDA review for Humira biosimilar

BioPharma Dive

Flag link:

Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Medical Marketing and Media

Flag link:

FDA revises biosimilar guidelines for clearer drug labelling

FDA revises biosimilar guidelines for clearer drug labelling

Pharmaceutical Technology

Flag link:

Sandoz to Commercialize Samsung Bioepis’ Biosimilar to J&J’s Stelara

Sandoz to Commercialize Samsung Bioepis’ Biosimilar to J&J’s Stelara

BioSpace

Samsung Bioepis

Flag link:

AbbVie’s Humira to Take Hit from Biosimilars, Next-Gen Therapies: Report

AbbVie’s Humira to Take Hit from Biosimilars, Next-Gen Therapies: Report

BioSpace

Crohn's Disease

Flag link:

Could This Biosimilar Drug Be Novartis' Next Blockbuster?

Could This Biosimilar Drug Be Novartis' Next Blockbuster?

Motley Fool

Flag link:

Novartis updates on Sandoz finances ahead of spin-off

Novartis updates on Sandoz finances ahead of spin-off

Pharmaphorum

Flag link:

FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri

FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri

BioSpace

multiple sclerosis

Flag link:

CVS Health Enters Biosimilars Market with Launch of Cordavis Subsidiary

CVS Health Enters Biosimilars Market with Launch of Cordavis Subsidiary

BioSpace

Flag link:

Novartis cites strong sales growth for $15B Sandoz spin-off as board vote unanimously for separation

Novartis cites strong sales growth for $15B Sandoz spin-off as board vote unanimously for separation

Biopharma Reporter

Flag link:

Novartis floats share distribution scheme as it plots Sandoz spinoff for Oct. 4

Novartis floats share distribution scheme as it plots Sandoz spinoff for Oct. 4

Fierce Pharma

Flag link:

Sandoz plans to enter the Eylea biosimilar race

Sandoz plans to enter the Eylea biosimilar race

Clinical Trials Arena

wet age-related macular degeneration

Flag link:

What’s Next In Biologics? Biosimilar Expert Predicts Big Fall Changes

What’s Next In Biologics? Biosimilar Expert Predicts Big Fall Changes

Forbes

Flag link:

Amgen's hyped Humira biosimilar fritters away its exclusivity advantage

Amgen's hyped Humira biosimilar fritters away its exclusivity advantage

Fierce Pharma

Flag link:

Biogen looks at selling biosims unit to longtime ally Samsung Bioepis: reports

Biogen looks at selling biosims unit to longtime ally Samsung Bioepis: reports

Fierce Pharma

Samsung Bioepis

Flag link:

Despite big Q2 declines for Humira and Imbruvica, AbbVie still boosts earnings guidance

Despite big Q2 declines for Humira and Imbruvica, AbbVie still boosts earnings guidance

Fierce Pharma

Flag link:

Biosimilar makers split strategies in bid to take on top-selling Humira

Biosimilar makers split strategies in bid to take on top-selling Humira

BioPharma Dive

Boehringer Ingelheim

Flag link:

Teva expands Alvotech collab with 2 more biosims, increased manufacturing oversight and a $40M investment

Teva expands Alvotech collab with 2 more biosims, increased manufacturing oversight and a $40M investment

Fierce Pharma

Teva Pharmaceutical

drug manufacturing

Flag link:

Pages